LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Accueil・Liste d'Actions・Editas Medicine Inc

Editas Medicine Inc

Ouvert

SecteurSoins de santé

3.37 -2.03

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.24

Max

3.52

Chiffres clés
By Trading Economics
Revenu	-19M -25M
Ventes	-22M 2.8M
BPA	-0.26
Marge bénéficiaire	-882.444
Employés	87
EBITDA	-19M -25M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+78.43% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-40M 254M
Ouverture précédente	5.4
Clôture précédente	3.37

Sentiment de l'Actualité

By Acuity

21%

79%

38 / 344 Classement par Healthcare

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 mai 2026, 22:47 UTC

Résultats

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mai 2026, 20:45 UTC

Résultats

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mai 2026, 22:37 UTC

Market Talk

Acquisitions, Fusions, Rachats

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mai 2026, 22:04 UTC

Acquisitions, Fusions, Rachats

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mai 2026, 22:04 UTC

Acquisitions, Fusions, Rachats

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mai 2026, 21:12 UTC

Résultats

Acquisitions, Fusions, Rachats

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mai 2026, 21:00 UTC

Résultats

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mai 2026, 20:57 UTC

Résultats

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:55 UTC

Résultats

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mai 2026, 20:48 UTC

Actions en Tendance

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mai 2026, 20:34 UTC

Résultats

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mai 2026, 20:31 UTC

Résultats

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mai 2026, 20:28 UTC

Résultats

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mai 2026, 20:26 UTC

Résultats

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:20 UTC

Résultats

Costco 3Q Membership Fees $1.37B

28 mai 2026, 20:20 UTC

Résultats

Costco 3Q Net Sales $69.15B

28 mai 2026, 20:19 UTC

Résultats

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mai 2026, 20:19 UTC

Résultats

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mai 2026, 20:17 UTC

Résultats

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mai 2026, 20:17 UTC

Résultats

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

78.43% hausse

Prévisions sur 12 Mois

Moyen 6.37 USD 78.43%

Haut 15 USD

Bas 4 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

38 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.